A separate study of a CAR targeting chondroitin sulfate proteoglycan 4 (CSPG4) showed reduced tumor growth in a xenograft model of the HNSCC cell line PCI-3024. This evidence concerns the gene CSPG4 and head and neck squamous cell carcinoma.